Valneva (VALN) Competitors $10.50 +0.13 (+1.25%) Closing price 04:00 PM EasternExtended Trading$10.48 -0.02 (-0.19%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, LNTH, MENS, SRRK, and ADMAShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Jyong Biotech (MENS), Scholar Rock (SRRK), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Lantheus Jyong Biotech Scholar Rock ADMA Biologics Valneva (NASDAQ:VALN) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Do analysts recommend VALN or CRNX? Valneva currently has a consensus price target of $15.00, suggesting a potential upside of 42.86%. Crinetics Pharmaceuticals has a consensus price target of $74.45, suggesting a potential upside of 67.58%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Crinetics Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has higher valuation & earnings, VALN or CRNX? Valneva has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$183.52M4.92-$13.25M-$0.98-10.71Crinetics Pharmaceuticals$1.39M3,005.92-$298.41M-$4.11-10.81 Do insiders and institutionals have more ownership in VALN or CRNX? 11.4% of Valneva shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to VALN or CRNX? In the previous week, Valneva had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 9 mentions for Valneva and 7 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.44 beat Valneva's score of 0.38 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, VALN or CRNX? Valneva has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Is VALN or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Valneva's net margin of -33.87%. Crinetics Pharmaceuticals' return on equity of -32.28% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-33.87% -34.78% -13.43% Crinetics Pharmaceuticals N/A -32.28%-29.45% SummaryValneva and Crinetics Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$902.27M$10.51B$6.04B$10.46BDividend YieldN/A1.89%5.73%4.79%P/E Ratio-10.7120.7585.3127.07Price / Sales4.9228.59586.80189.44Price / Cash106.1325.5625.7330.17Price / Book4.363.3712.666.69Net Income-$13.25M$210.63M$3.31B$276.03M7 Day Performance-4.72%-2.66%-0.44%-1.14%1 Month Performance17.45%0.53%8.70%6.49%1 Year Performance86.50%-6.40%76.79%34.44% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.3096 of 5 stars$10.50+1.3%$15.00+42.9%+84.2%$902.27M$183.52M-10.71700Gap UpCRNXCrinetics Pharmaceuticals3.7983 of 5 stars$41.68+2.0%$74.45+78.6%-15.4%$3.85B$1.04M-10.14210ZLABZai Lab2.6431 of 5 stars$33.31-1.3%$56.35+69.2%+19.4%$3.77B$398.99M-16.331,869News CoveragePositive NewsAKROAkero Therapeutics3.6704 of 5 stars$46.04-0.1%$81.14+76.2%+81.8%$3.69BN/A-23.0230Analyst DowngradeACADACADIA Pharmaceuticals4.5074 of 5 stars$21.59-1.0%$29.12+34.9%+34.5%$3.68B$1.02B16.23510Gap UpAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600Gap UpMIRMMirum Pharmaceuticals3.111 of 5 stars$72.53-0.6%$76.50+5.5%+81.3%$3.66B$336.89M-59.94140LNTHLantheus4.5619 of 5 stars$52.70-2.1%$85.50+62.2%-52.3%$3.66B$1.53B14.02700MENSJyong BiotechN/A$52.01+8.4%N/AN/A$3.65BN/A0.0031SRRKScholar Rock4.7181 of 5 stars$39.80+6.2%$46.40+16.6%+48.8%$3.60BN/A-13.68140Options VolumeGap DownADMAADMA Biologics3.4688 of 5 stars$14.07-4.0%$27.67+96.6%-15.2%$3.50B$426.45M16.36530Positive News Related Companies and Tools Related Companies CRNX Alternatives ZLAB Alternatives AKRO Alternatives ACAD Alternatives AAPG Alternatives MIRM Alternatives LNTH Alternatives MENS Alternatives SRRK Alternatives ADMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
